|
| |
Hybrigenics: 2007 Revenues, Significant Progress in
Cancer-related R&D Programmes
Paris, 18 March 2008 - Hybrigenics, a
bio-pharmaceutical company with a focus on research and development of new
cancer treatments and specialized in protein-protein interactions, today
announces its revenues for the year ended 31 December 2007.
2007 revenues
EUR m
2007 2006
Hybrigenics Pharma
0.45 0.34
Hybrigenics Services 2.45
2.46
Other operating income 0.5
1.0
Total
3.4 3.8
Revenues from scientific services rose by 3.4 percent to EUR 2.9m in 2007.
Billings outside France reached EUR 1.56m, accounting for more than half of the
total (59 percent) and representing a 30 percent increase on 2006 (EUR 1.21m).
The "other operating income" item consists mainly of rents received from biotech
companies housed within Hybrigenics' premises. The departures of Diatos, Fovea
Pharmaceuticals and DBV-Technologies, which left for larger facilities, were not
fully offset by the arrivals of Neovacs, Biocortech and Sepal Pharma. In
addition, some vacated space was set aside for the expansion of Hybrigenics' own
activities.
Significant progress in cancer-related R&D programmes
Inecalcitol: very good tolerance at the daily oral dose of 80 microgrammes
The clinical development of inecalcitol, a vitamin D analogue, is
progressing swiftly. The tolerance Phase II trial started with the treatment of
the first patient in November 2007, and is now ongoing at six centers in France:
the Georges Pompidou, Saint-Joseph and Beaujon Hospitals and Institut Curie in
Paris, the Cancer Centre Lacassagne in Nice and the University Hospital in
Besançon. Three cohorts of patients are currently being treated, and the highest
dose is 80 microgrammes per day, taken orally, for 18 weeks. No signs of
hypercalcemia, which is the major side-effect of natural vitamin D, have been
observed to date.
Ubiquitin-specific protease inhibitors: selection of HBX 99200
Hybrigenics' research programme focusing on new anti-cancer molecules has
been validated by results obtained by the US National Cancer Institute. After in
vitro tests on 60 cell lines and in vivo research in mice, HBX 99,200 has been
selected for evaluation in rats that will receive grafts of prostate cancer,
breast cancer and melanoma cells. HBX 99,200 is an inhibitor of ubiquitin-specific
proteases, which is a new class of therapeutic targets for cancer treatment.
Appointment
Eric Cohen, Chief Financial Officer, has been promoted to Deputy Managing
Director in charge of the Services business.
About Hybrigenics
Hybrigenics is a bio-pharmaceutical company focusing its internal R&D
programmes on innovative targets and therapies for the treatment of cancer.
Hybrigenics' development programme is based on inecalcitol, a vitamin D analogue
more powerful and less toxic than calcitriol, the naturally active form of
vitamin D. Inecalcitol is being developed for the treatment of hormone-resistant
prostate cancer in combination with Sanofi-Aventis' Taxotere(R), which is the
current gold-standard chemotherapeutic treatment for this indication.
Hybrigenics' research programme explores the role of enzymes known as ubiquitin-specific
proteases (USP) in the degradation of onco-proteins, and the effectiveness of
proprietary USP inhibitors in treating various types of cancer.
Hybrigenics also offers a range of services to identify, validate and inhibit
protein interactions to researchers in all areas of life sciences through its
Hybrigenics Services unit, using its ISO 9001-certified high-throughput
Yeast-Two Hybrid (Y2H) screening platform, its sophisticated bioinformatics
tools and extensive database, along with its chemical library and chemical
screening platform.
Hybrigenics
Eric Cohen
CFO
Tél. : +33 (0)1 58 10 38 00
investors@hybrigenics.com
NewCap.
Financial communication
Axelle Vuillermet / Pierre Laurent
Tél. : +33 (0)1 44 71 94 94
hybrigenics@newcap.fr
For further information, please contact:
Andrew Lloyd & Associates
Andrew Lloyd / Neil Hunter
Tel: +44 1273 675100
allo@ala.com /
neil@ala.com
| |
|
